How to buy BioXcel Therapeutics stock | $53.88

BioXcel Therapeutics, Inc is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars. BioXcel Therapeutics employs 31 staff and has a market cap (total outstanding shares value) of USD$1.2 billion.

How to buy shares in BioXcel Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for BioXcel Therapeutics. Find the stock by name or ticker symbol: BTAI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioXcel Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$53.88, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioXcel Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of BioXcel Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BioXcel Therapeutics share price

Use our graph to track the performance of BTAI stocks over time.

BioXcel Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-19.

Latest market close	USD$53.88
52-week range	USD$3.76 - USD$71.5
50-day moving average	USD$46.0121
200-day moving average	USD$44.3467
Wall St. target price	USD$110.89
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.766

Buy BioXcel Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy BioXcel Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioXcel Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioXcel Therapeutics price performance over time

Historical closes compared with the close of $53.88 from 2020-11-16

1 week (2020-11-25)	20.67%
1 month (2020-11-06)	1.53%
3 months (2020-09-04)	31.25%
6 months (2020-06-05)	12.91%

1 year (2019-12-05)	748.50%
2 years (2018-12-04)	1,008.64%
3 years (2017-12-02)	N/A
5 years (2015-12-02)	N/A

BioXcel Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-64.42%
Return on equity TTM	-136.53%
Profit margin	0%
Book value	$2.623
Market capitalisation	USD$1.2 billion

TTM: trailing 12 months

Shorting BioXcel Therapeutics shares

There are currently 2.7 million BioXcel Therapeutics shares held short by investors – that's known as BioXcel Therapeutics's "short interest". This figure is 16.9% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting BioXcel Therapeutics shares can be evaluated.

BioXcel Therapeutics's "short interest ratio" (SIR)

BioXcel Therapeutics's "short interest ratio" (SIR) is the quantity of BioXcel Therapeutics shares currently shorted divided by the average quantity of BioXcel Therapeutics shares traded daily (recently around 515802.49042146). BioXcel Therapeutics's SIR currently stands at 5.22. In other words for every 100,000 BioXcel Therapeutics shares traded daily on the market, roughly 5220 shares are currently held short.

However BioXcel Therapeutics's short interest can also be evaluated against the total number of BioXcel Therapeutics shares, or, against the total number of tradable BioXcel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioXcel Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 BioXcel Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.2127% of the tradable shares (for every 100,000 tradable BioXcel Therapeutics shares, roughly 213 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioXcel Therapeutics.

Find out more about how you can short BioXcel Therapeutics stock.

BioXcel Therapeutics share dividends

We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.

BioXcel Therapeutics share price volatility

Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $3.76 up to $71.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 1.6264. This would suggest that BioXcel Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

BioXcel Therapeutics overview

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Frequently asked questions

• What percentage of BioXcel Therapeutics is owned by insiders or institutions?

  Currently 48.511% of BioXcel Therapeutics shares are held by insiders and 28.522% by institutions.

• How many people work for BioXcel Therapeutics?

  Latest data suggests 31 work at BioXcel Therapeutics.

• When does the fiscal year end for BioXcel Therapeutics?

  BioXcel Therapeutics's fiscal year ends in December.

• Where is BioXcel Therapeutics based?

  BioXcel Therapeutics's address is: 555 Long Wharf Drive, New Haven, CT, United States, 06511

• What is BioXcel Therapeutics's CUSIP number?

  BioXcel Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09075P105